Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Executive Summary

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

Advertisement

Related Content

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Mylan/Gilead, AbbVie/MPP boost access to HIV medicines
US Senate clears PEPFAR bill with HIV treatment thresholds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100507

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel